
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is also expanding its sales team, which may result in a temporary increase in cash burn, but overall the company has plenty of cash on hand. Additionally, the company's first quarter results in 2026 were strong, with a higher gross margin and increased guidance for key metrics in 2026. The company also remains on track to commercially launch its patch product by the end of 2027, potentially adding to its growth prospects.
Bears say
Beta Bionics is facing several potential risks, including the possibility of failing to gain market share or increase penetration in the pharmacy channel, delays in clinical development, and challenges with adoption in the Type 2 diabetes market. Additionally, initiatives proposed by CMS, shareholder dilution, and regulatory actions could also pose threats to the company's future growth and profitability. While the recent increase in pharmacy new starts and sales force expansion may provide short-term positives, the company's fundamental outlook is uncertain and may face downward pressure if these risks materialize.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares